Trihexyphenidyl (hydrochloride) – 500 mg

Brand:
Cayman
CAS:
52-49-3
Storage:
-20
UN-No:
Non-Hazardous - /

Trihexyphenidyl is an antagonist of M1 muscarinic acetylcholine receptors.{45595} It binds to rat M1 receptors in cerebral cortex selectively over rat M2 receptors in heart tissue (IC50s = 3.7 and 31 nM, respectively). Trihexyphenidyl inhibits contractions induced by acetylcholine (Item No. 23829) in guinea pig ileum (IC50 = 22 nM).{46375} It also inhibits oxotremorine-induced tremors and physostigmine-induced mortality in mice (ED50s = 2 and 3.6 mg/kg, respectively). Trihexyphenidyl (20 mg/kg) improves abnormal movement in a mouse model of L-3,4-dihydroxyphenylalanine (L-DOPA) responsive dystonia (DRD) that expresses mutant tyrosine hydroxylase (TH).{45596} Formulations containing trihexyphenidyl have been used in the symptomatic treatment of Parkinson’s disease.  

 

Available on backorder

SKU: 27643 - 500 mg Category:

Description

An M1 receptor antagonist; binds to rat M1 receptors in cerebral cortex selectively over rat M2 receptors in heart tissue (IC50s = 3.7 and 31 nM, respectively); inhibits acetylcholine-induced contractions in guinea pig ileum (IC50 = 22 nM); inhibits oxotremorine-induced tremors and physostigmine-induced mortality in mice (ED50s = 2 and 3.6 mg/kg, respectively); improves abnormal movement in a DRD mouse model that expresses mutant TH at 20 mg/kg


Formal name: α-cyclohexyl-α-phenyl-1-piperidinepropanol, monohydrochloride

Synonyms:  Benzhexol hydrochloride

Molecular weight: 337.9

CAS: 52-49-3

Purity: ≥98%

Formulation: A solid


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease